The Disproportionate Rise in Pancreatic Cancer in Younger Women Is Due to a Rise in Adenocarcinoma and Not Neuroendocrine Tumors: A Nationwide Time-Trend Analysis Using 2001–2018 United States Cancer Statistics Databases
by
, , , ,
Yi Jiang
1,*
,
Yazan Abboud
1,
Jeff Liang
1,
Brent Larson
2,
Arsen Osipov
3,
Jun Gong
3
,
Andrew E. Hendifar
3,
Katelyn Atkins
4,
Quin Liu
1,
Nicholas N. Nissen
5,
Debiao Li
6,
Stephen J. Pandol
1,
Simon K. Lo
1 and
Srinivas Gaddam
1,* 1
Karsh Division of Gastroenterology, Departments of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
2
Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
3
Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
4
Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
5
Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
6
Biomedical Imaging Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
*
Authors to whom correspondence should be addressed.
Cancers 2024, 16(5), 971; https://doi.org/10.3390/cancers16050971
Submission received: 28 January 2024
/
Revised: 25 February 2024
/
Accepted: 26 February 2024
/
Published: 28 February 2024
(This article belongs to the Special Issue Sex Differences in Cancer)
Abstract
:Simple Summary
Previous studies have noted a significant increase in the incidence of pancreatic cancer among younger women (15–54 years) compared to men in the United States, yet the specific histopathologic types remained unexplored. This study aimed to elucidate whether the disproportionate rise in the incidence of pancreatic cancer in younger women was predominantly attributed to pancreatic ductal adenocarcinoma (PDAC) or pancreatic neuroendocrine tumors (PanNET). Our analysis revealed that the age-adjusted incidence rates (aIRs) of PDAC in younger women increased at a greater rate than counterpart men, whereas PanNET did not demonstrate a statistically significant sex-specific average annual percentage change difference. These discoveries provide crucial insights for guiding future investigations and informing healthcare policy.
Abstract
In previous studies, a significant increase in the incidence of pancreatic cancer among younger women compared to men in the United States was noted. However, the specific histopathologic characteristics were not delineated. This population-based study aimed to assess whether this disproportionate rise in pancreatic cancer in younger women was contributed by pancreatic ductal adenocarcinoma (PDAC) or pancreatic neuroendocrine tumors (PanNET). The United States Cancer Statistics (USCS) database was used to identify patients with pancreatic cancer between 2001 and 2018. The results showed that, in younger adults, the incidence of PDAC has increased in women [average annual percentage change (AAPC) = 0.62%], while it has remained stable in men (AAPC = −0.09%). The PDAC incidence rate among women increased at a greater rate compared to men with a statistically significant difference in AAPC (p < 0.001), with neither identical nor parallel trends. In contrast, cases of PanNET did not demonstrate a statistically significant sex-specific AAPC difference. In conclusion, this study demonstrated that the dramatic increase in the incidence rate of PDAC explains the disproportionate rise in pancreatic cancer incidence in younger women. This prompts further prospective studies to investigate the underlying reasons for these sex-specific disparities in PDAC.
1. Introduction
Globally, pancreatic cancer has become the third leading cause of cancer-related deaths, with a rising incidence [1]. More than 95% of pancreatic cancers arise from the exocrine elements, with pancreatic ductal adenocarcinoma (PDAC) accounting for the majority of pancreatic neoplasms [2]. Pancreatic neuroendocrine tumors (PanNET), arising from the endocrine pancreas, comprise less than 5% of pancreatic neoplasms. A previous study analyzing the Surveillance, Epidemiology, and End Results Program (SEER) database showed a greater relative increase in the incidence of pancreatic cancer among women younger than the age of 55 compared to counterpart men [3]. Despite the concerning findings, little is known regarding the histopathological subtype of pancreatic cancer that is contributing to this rapid rise in incidence among younger women. This study aimed to perform an age and sex-specific time–trend analysis of the age-adjusted incidence rates (aIRs) of PDAC and PanNET using the United States Cancer Statistics (USCS) database (Available online: www.cdc.gov/cancer/uscs/public-use (accessed on 23 October 2021).), which represents nearly 100% of the US population [4].
2. Materials and Methods
This is a retrospective analysis of prospectively collected data in the National Program of Cancer Registries (NPCR) [5] and the Surveillance, Epidemiology, and End Results Program (SEER) [6], which comprise the United States Cancer Statistics (USCS) databases. SEER*stat software [version 8.3.9.2, National Cancer Institute (NCI), Bethesda, MD] was used to retrieve cases of cancer in which the pancreas was the primary site and that were diagnosed between 2001 to 2018 using the International Classification of Diseases-Oncology-3 (ICD-O-3) codes (Appendix A) [7]. Only cases with malignant behavior were included. The primary outcomes were the PDAC and PanNET sex-specific trends and age-adjusted incidence rates (aIRs) per 100,000 population among multiple age-specified groups. This database did not contain any protected health information. Given that both the SEER and NPCR databases are de-identified and publicly available, institutional review board approval was not required.
To investigate the robustness of our findings, sensitivity analyses were performed to examine the age and sex-specific time trends of the aIRs of PDAC and PanNET exclusively in cases with microscopically confirmed diagnosis. The sex-specific trends and aIRs among multiple histology-specified groups in microscopically confirmed younger adult (15–54 years) PDAC cases were also analyzed. In some situations, PDAC and PanNET are difficult to distinguish, particularly in the poorly differentiated or undifferentiated subgroups [8]. We performed a sensitivity analysis while excluding the poorly and undifferentiated subgroups, using restricted PDAC and PanNET ICD-O-3 codes (Appendix A).
For age-specific analyses, we divided the age groups into 15–54 years of age (younger adults) and more than or equal to 55 years of age (older adults). The younger adults were further categorized into two equal-age subgroups. This subsequent analysis was performed in the 35–54 years and 15–34 years age groups.
The joinpoint regression program (v4.9.0.1, NCI, Bethesda, MD, USA) was used to assess trends. AIRs were calculated per 100,000 population (age-adjusted to the US population in the year 2000). The annual percentage change and average annual percentage change (APC and AAPC) were calculated. The quantification of time trends was performed using Monte Carlo permutation analysis to fit the simplest joinpoint model. Pairwise comparison was used to assess identicalness and parallelism. Statistical significance was defined as a 2-sided p-value cut-off of 0.05. p-value < 0.025 was considered statistically significant for the post hoc age subgroups.
3. Results
Between 2001 and 2018, 748,132 patients were diagnosed with pancreatic cancer (aIR 12.35/100,000). Of these, 694,661 patients had PDAC (92.9% of all pancreatic cancer cases; 49.5% women; aIR 11.46/100,000). The >55 year-old age group represented 89.8% and the 15–54 year-old age group represented 10.2% of all PDAC cases. There were 42,806 patients diagnosed with PanNET (5.7% of all pancreatic cancer cases; 45.3% women; aIR 0.71/100,000). The >55 year-old age group represented 69.6% and the 15–54 year-old age group represented 30.3% of all PanNET cases.
The overall aIRs for PDAC significantly increased in both women and men of all ages and older adults without a significant difference. In younger adults, the aIR of PDAC increased in women [AAPC = 0.62% (95% CI 0.30%–0.94%), p < 0.001] but remained stable in men [AAPC = −0.09% (95% CI −0.32%–0.14%), p = 0.44]. There was a statistically significant difference in AAPC: −0.71% (95% CI −1.07%–−0.34%, p < 0.001). These trends were non-identical (p < 0.001) and non-parallel (p = 0.02), suggesting that the aIR among women increased at a greater rate than in men. This sex disparity was most significant in the 35–54 year-old age subgroup (Table 1, Figure 1).
Cases of PanNET did not demonstrate a statistically significant sex-specific AAPC difference. The aIRs of PanNET increased in both women and men in the prespecified age groups, including all ages, older adults, and younger adults (15–34 and 35–54 year-old age subgroups) (Table 2, Figure 2).
The results from the sensitivity analyses were consistent with the primary analysis (Supplemental Tables S1 and S2).
Trend analyses on histologic subgroups were performed on microscopically confirmed PDAC in younger adults (Supplemental Table S3). A PDAC subgroup that was not otherwise specified (NOS) (74.6% of all PDAC subtypes) demonstrated sex disparity, in which the aIRs among women [AAPC = 1.02% (95% CI 0.68%–1.37%), p < 0.001] increased at a greater rate compared to men [AAPC = 0.37% (95% CI 0.05%–0.68%), p = 0.03], with a statistically significant difference of −0.66% (95% CI −1.09%–−0.23%, p = 0.003); these were non-identical (p < 0.001) trends. Other histologic subtypes (intraductal papillary mucinous neoplasm, adenosquamous carcinoma, medullary carcinoma, signet ring cell carcinoma, cystic adenocarcinoma) were too few to estimate a trend. Mucinous PDAC showed similarly decreasing trends of aIRs in both sex groups (p = 0.18).
4. Discussion
This study showed a greater increase in aIR in younger adult women compared to counterpart men with PDAC but not with PanNET. These trends were statistically different and non-identical. Further evaluation showed that PDAC, NOS (ICD-O-3 code specified as 8140) was likely contributed to this sex disparity in young adults with PDAC.
The exact cause of this notably increased incidence of PDAC in younger women remains unknown, but is likely linked to imbalanced risk factors [9]. Smoking and tobacco use have been recognized as the primary risk factor for young-onset pancreatic cancer [10,11,12]. According to a Swedish prospective, population-based study, while regular smoking is considered as a risk factor for both sexes, occasional and passive smoking were identified as significant risk factors only for women [13]. With improved smoking cessation interventions, a significant reduction in tobacco use amongst young people has been noted globally, along with a decline in disease-adjusted life years attributed to tobacco use, particularly in younger women [10]. Heavy alcohol consumption is directly linked to an increased risk of pancreatic cancer [9] and indirectly associated with pancreatitis, a well-established risk factor for this disease [14]. Historically, men drank more and experienced more alcohol-related harm; however, a recent trend suggests convergence. A meta-analysis demonstrated a trend towards the closing of the sex gap in alcohol consumption and its associated harms. This finding suggests a rising prevalence of alcohol consumption and its adverse effects in women, especially among the younger cohort born in the late 1990s [15]. Previous publications highlighted the essential role of estrogen-related receptor γ in pancreatic acinar cell function; the suggested reproductive factors may contribute to the onset of pancreatic diseases [16]. Research on the association between reproductive factors and the risk of PDAC has shown heterogenous results. Some studies have suggested that high parity [17,18], having had two children [19], and a cumulative breastfeeding duration of over 24 months [20] are associated with a decreased risk of pancreatic cancer. However, subsequent large cohort studies [21,22] have failed to identify a strong association between reproductive factors and pancreatic cancer risk. Similarly, there are controversial results regarding the association between the use of exogenous hormones and the risk of pancreatic cancer [23,24,25]. Later, it was proposed that polymorphism in estrogen-related genes may contribute to PDAC susceptibility, with a distinct molecular landscape particularly associated with young-onset PDAC [26,27,28].
On the other end, the incidence of PanNET was found to be consistently increasing across all age groups without significant sex disparity. These findings are consistent with previous studies [29,30]. It was suspected that the rising incidence of PanNET is largely attributed to the increased detection of asymptomatic disease due to the heightened awareness and the expanded utilization of abdominal imaging [31] and endoscopy [32]. Despite both PanNET and PDAC being associated with potential risk factors such as smoking, heavy alcohol use, and diabetes [33], the patterns of these risk factors and the extent of their impact differ. Further investigation is needed to elucidate the role of PDAC-exclusive risk factors in contributing to the observed sex disparity.
Previous studies suspected that the greater increase in the aIRs of pancreatic cancer in younger women could be attributed to the accelerating incidence of histologic subtypes that are more common in women, such as cystic PDAC and solid pseudopapillary neoplasm (SPN) [34]; however, our study does not show the same findings. SPNs (which occur predominantly in young women) were excluded from our analysis given that they are different from PDAC or PanNET. Our findings further confirm that it is the NOC PDAC subtype that is responsible for the sex disparity.
Given the ICD code-based data extraction, the limitations of this study include known issues with the coding accuracy achievable with large databases, a lack of information on major modifiable risk factors in the database, including obesity, smoking, and alcohol consumption, as well as a lack of information on their sex-specific, age-specific, or region-specific effects. The strengths of this study include a strong statistical methodology, such as testing for identicalness and parallelism. Sensitivity analyses confirmed the robustness of our findings.
5. Conclusions
Using nationwide data representing nearly 100% of the US population, we demonstrated that the disproportionate rise in the incidence of pancreatic cancer in younger women is explained by the PDAC histological subtype. PanNET, which does not share the same pattern of common risk factors with PDAC, appears to be increasing equally in both men and women. This raises further questions about the cause of this sex disparity in PDAC. Further prospective population-based studies with age–period modeling and the adjustment of potential lifestyle-related confounders are needed to explore sex-based disproportional exposure to PDAC-exclusive risk factors.
Supplementary Materials
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers16050971/s1, Supplemental Table S1: Sex-specific Trends for Biopsy-proven Pancreatic Ductal Adenocarcinoma (PDAC) and Pancreatic Neuroendocrine Tumor (PanNET) Stratified by Age Groups; Supplementary Table S2: Sex-specific Trends for restricted ICD-O-3 codes-based Pancreatic Ductal Adenocarcinoma (PDAC) and Pancreatic Neuroendocrine Tumor (PanNET) Stratified by Age Groups; Supplemental Table S3: Sex-specific Trends for Young adult (aged 15–54 years) Biopsy-Proven Pancreatic Ductal Adenocarcinoma (PDAC) Stratified by Histologic Groups.
Author Contributions
Conceptualization, S.G., Q.L., J.G. and Y.J.; methodology, S.G., Y.J., Y.A., J.L., B.L., A.O., N.N.N., J.G., Q.L. and K.A.; software, Y.A; validation, Y.J., Y.A., N.N.N., B.L. and S.G.; formal analysis, Y.A.; investigation, J.L., B.L., A.O., J.G. and A.E.H.; resources, B.L., A.O., K.A., Q.L, N.N.N., D.L., S.J.P. and S.K.L.; data curation, Y.J., Y.A., A.O., K.A., A.E.H., S.J.P., S.K.L. and J.L.; writing—original draft preparation, Y.J.; writing—review and editing, Y.J., Y.A., J.L., K.A. and Q.L; visualization, A.E.H., S.J.P., S.K.L., B.L., D.L., N.N.N. and D.L.; supervision, A.E.H., S.J.P., S.K.L., D.L., J.G. and S.G.; project administration, N.N.N., Q.L., S.K.L. and S.G.; funding acquisition, S.G. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Ethical review and approval were waived for this study given that both the SEER and NPCR databases are de-identified and publicly available; neither database contains any protected health information.
Informed Consent Statement
Not applicable.
Data Availability Statement
Publicly available datasets were analyzed in this study. These data can be found here: https://www.cdc.gov/cancer/uscs/public-use/, accessed on 23 October 2021.
Acknowledgments
We acknowledge and thank the review comments and suggestions from Shelly Lu, Kenneth Hyunsoo Park, Rabindra Watson, Jenan Ghaith and Daniel Lew.
Conflicts of Interest
The authors declare no conflicts of interest.
Appendix A
Using the ICD-O-3, PDAC was defined as the following codes: 8000–8003, 8010, 8012, 8020–8022, 8030–8033, 8041–8042, 8050, 8052, 8140–8141, 8143–8144, 8211, 8230, 8260–8263, 8310, 8440–8441, 8450, 8470–8471, 8480–8481, 8490, 8500, 8503–8504, 8510, 8521, 8550, 8560, and 8570. PanNET was defined as 8150–8156, 8240–8241, 8246, 8249, and 9473. PDAC histologic subtypes were defined as the following codes: adenocarcinoma, not otherwise specified (NOS) (8140), ductal specified as mucinous adenocarcinoma (8480, 8481), and ductal specified as cystic adenocarcinoma (8440, 8470, 8504). Other specific PDAC types were as follows: ductal specified as arising from an intraductal papillary mucinous neoplasm (IPMN) (8450, 8453, 8471, 8503), adenosquamous carcinoma (8560, 8052), medullary carcinoma (8510), and signet ring cell carcinoma (8490).
Sensitivity analysis was performed based on restricted PDAC ICD-O-3 codes (8000, 8001, 8010, 8050, 8140, 8144, 8211, 8230, 8260–8263, 8310, 8481, 8500, 8521, 8570) and restricted PanNET codes (8150–8153, 8155–8156, 8240–8241, 8249).
References
- Siegel, R.L.; Giaquinto, A.N.; Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 2024, 74, 12–49. [Google Scholar] [CrossRef] [PubMed]
- Park, W.; Chawla, A.; O’Reilly, E.M. Pancreatic Cancer: A Review. JAMA 2021, 326, 851–862. [Google Scholar] [CrossRef] [PubMed]
- Gaddam, S.; Abboud, Y.; Oh, J.; Samaan, J.S.; Nissen, N.N.; Lu, S.C.; Lo, S.K. Incidence of Pancreatic Cancer by Age and Sex in the US, 2000–2018. JAMA 2021, 326, 2075–2077. [Google Scholar] [CrossRef] [PubMed]
- National Program of Cancer Registries and Surveillance, Epidemiology, and End Results Program SEER*Stat Database: NPCR and SEER Incidence—U.S. Cancer Statistics Public Use Research Database. 2020 Submission (2001–2018). Available online: www.cdc.gov/cancer/uscs/public-use (accessed on 23 October 2021).
- National Program of Cancer Registries. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Available online: https://www.cdc.gov/cancer/npcr/about/ (accessed on 23 December 2023).
- Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence—SEER Research Data, 9 Registries. National Cancer Institute, DCCPS, Surveillance Research Program. Available online: www.seer.cancer.gov (accessed on 7 October 2021).
- Fritz, A.; Percy, C.; Jack, A.; Shanmugaratnam, K.; Sobin, L.H.; Parkin, D.M.; Whelan, S.L. International Classification of Diseases for Oncology, 3rd ed.; (ICD-O-3); World Health Organization: Geneva, Switzerland, 2000. [Google Scholar]
- Konukiewitz, B.; Jesinghaus, M.; Steiger, K.; Schlitter, A.M.; Kasajima, A.; Sipos, B.; Zamboni, G.; Weichert, W.; Pfarr, N.; Klöppel, G. Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3. Hum. Pathol. 2018, 77, 70–79. [Google Scholar] [CrossRef] [PubMed]
- Klein, A.P. Pancreatic cancer epidemiology: Understanding the role of lifestyle and inherited risk factors. Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 493–502. [Google Scholar] [CrossRef] [PubMed]
- Dahia, S.S.; Konduru, L.; Pandol, S.J.; Barreto, S.G. The burden of young-onset pancreatic cancer and its risk factors from 1990 to 2019: A systematic analysis of the global burden of disease study 2019. Pancreatology 2024, 24, 119–129. [Google Scholar] [CrossRef] [PubMed]
- Piciucchi, M.; Capurso, G.; Valente, R.; Larghi, A.; Archibugi, L.; Signoretti, M.; Stigliano, S.; Zerboni, G.; Barucca, V.; La Torre, M.; et al. Early onset pancreatic cancer: Risk factors, presentation and outcome. Pancreatology 2015, 15, 151–155. [Google Scholar] [CrossRef]
- Collaborators, G.P.C. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 2019, 4, 934–947. [Google Scholar] [CrossRef]
- Andersson, G.; Wennersten, C.; Borgquist, S.; Jirström, K. Pancreatic cancer risk in relation to sex, lifestyle factors, and pre-diagnostic anthropometry in the Malmö Diet and Cancer Study. Biol. Sex. Differ. 2016, 7, 66. [Google Scholar] [CrossRef]
- Yadav, D.; Lowenfels, A.B. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 2013, 144, 1252–1261. [Google Scholar] [CrossRef]
- Slade, T.; Chapman, C.; Swift, W.; Keyes, K.; Tonks, Z.; Teesson, M. Birth cohort trends in the global epidemiology of alcohol use and alcohol-related harms in men and women: Systematic review and metaregression. BMJ Open 2016, 6, e011827. [Google Scholar] [CrossRef] [PubMed]
- Choi, J.; Oh, T.G.; Jung, H.W.; Park, K.Y.; Shin, H.; Jo, T.; Kang, D.S.; Chanda, D.; Hong, S.; Kim, J.; et al. Estrogen-Related Receptor γ Maintains Pancreatic Acinar Cell Function and Identity by Regulating Cellular Metabolism. Gastroenterology 2022, 163, 239–256. [Google Scholar] [CrossRef] [PubMed]
- Zhu, B.; Zou, L.; Han, J.; Chen, W.; Shen, N.; Zhong, R.; Li, J.; Chen, X.; Liu, C.; Shi, Y.; et al. Parity and pancreatic cancer risk: Evidence from a meta-analysis of twenty epidemiologic studies. Sci. Rep. 2014, 4, 5313. [Google Scholar] [CrossRef]
- Guan, H.B.; Wu, L.; Wu, Q.J.; Zhu, J.; Gong, T. Parity and pancreatic cancer risk: A dose-response meta-analysis of epidemiologic studies. PLoS ONE 2014, 9, e92738. [Google Scholar] [CrossRef] [PubMed]
- Archibugi, L.; Graglia, B.; Valente, R.; Stigliano, S.; Roberto, M.; Capalbo, C.; Marchetti, P.; Nigri, G.; Capurso, G. Gynecological and reproductive factors and the risk of pancreatic cancer: A case-control study. Pancreatology 2020, 20, 1149–1154. [Google Scholar] [CrossRef] [PubMed]
- Alvarez, A.; Benjaminsen Borch, K.; Rylander, C. Reproductive Factors, Use of Exogenous Hormones, and Pancreatic Cancer Incidence: The Norwegian Women and Cancer Study. Clin. Epidemiol. 2021, 13, 67–80. [Google Scholar] [CrossRef]
- Navarro Silvera, S.A.; Miller, A.B.; Rohan, T.E. Hormonal and reproductive factors and pancreatic cancer risk: A prospective cohort study. Pancreas 2005, 30, 369–374. [Google Scholar] [CrossRef]
- Stevens, R.J.; Roddam, A.W.; Green, J.; Pirie, K.; Bull, D.; Reeves, G.K.; Beral, V.; Collaborators, M.W.S. Reproductive history and pancreatic cancer incidence and mortality in a cohort of postmenopausal women. Cancer Epidemiol. Biomark. Prev. 2009, 18, 1457–1460. [Google Scholar] [CrossRef]
- Teng, Y.; Saito, E.; Abe, S.K.; Sawada, N.; Iwasaki, M.; Yamaji, T.; Shimazu, T.; Sasazuki, S.; Inoue, M.; Tsugane, S.; et al. Female reproductive factors, exogenous hormone use, and pancreatic cancer risk: The Japan Public Health Center-based prospective study. Eur. J. Cancer Prev. 2017, 26, 378–384. [Google Scholar] [CrossRef]
- Andersson, G.; Borgquist, S.; Jirström, K. Hormonal factors and pancreatic cancer risk in women: The Malmö Diet and Cancer Study. Int. J. Cancer 2018, 143, 52–62. [Google Scholar] [CrossRef]
- Butt, S.A.; Lidegaardi, Ø.; Skovlund, C.; Hannaford, P.C.; Iversen, L.; Fielding, S.; Mørch, L.S. Hormonal contraceptive use and risk of pancreatic cancer-A cohort study among premenopausal women. PLoS ONE 2018, 13, e0206358. [Google Scholar] [CrossRef] [PubMed]
- Chen, Q.; Yuan, H.; Shi, G.D.; Wu, Y.; Liu, D.F.; Lin, Y.T.; Chen, L.; Ge, W.L.; Jiang, K.; Miao, Y. Association between NR5A2 and the risk of pancreatic cancer, especially among Caucasians: A meta-analysis of case-control studies. Onco Targets Ther. 2018, 11, 2709–2723. [Google Scholar] [CrossRef] [PubMed]
- Peduzzi, G.; Archibugi, L.; Katzke, V.; Gentiluomo, M.; Capurso, G.; Milanetto, A.C.; Gazouli, M.; Goetz, M.; Brenner, H.; Vermeulen, R.C.H.; et al. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Sci. Rep. 2022, 12, 18100. [Google Scholar] [CrossRef] [PubMed]
- Ogobuiro, I.; Baca, Y.; Ribeiro, J.R.; Walker, P.; Wilson, G.C.; Gulhati, P.; Marshall, J.L.; Shroff, R.T.; Spetzler, D.; Oberley, M.J.; et al. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer. JCO Precis. Oncol. 2023, 7, e2300152. [Google Scholar] [CrossRef] [PubMed]
- Dasari, A.; Shen, C.; Halperin, D.; Zhao, B.; Zhou, S.; Xu, Y.; Shih, T.; Yao, J.C. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017, 3, 1335–1342. [Google Scholar] [CrossRef] [PubMed]
- Halfdanarson, T.R.; Bamlet, W.R.; McWilliams, R.R.; Hobday, T.J.; Burch, P.A.; Rabe, K.G.; Petersen, G.M. Risk factors for pancreatic neuroendocrine tumors: A clinic-based case-control study. Pancreas 2014, 43, 1219–1222. [Google Scholar] [CrossRef] [PubMed]
- Smith-Bindman, R.; Kwan, M.L.; Marlow, E.C.; Theis, M.K.; Bolch, W.; Cheng, S.Y.; Bowles, E.J.A.; Duncan, J.R.; Greenlee, R.T.; Kushi, L.H.; et al. Trends in Use of Medical Imaging in US Health Care Systems and in Ontario, Canada, 2000–2016. JAMA 2019, 322, 843–856. [Google Scholar] [CrossRef] [PubMed]
- Leeds, J.; Awadelkarim, B.; Lam, K.; Maheshwari, P.; Nayar, M.; Johnson, S.; Oppong, K.O.; Unit, H. O39 Trends in Pancreatic Cystic Lesions Undergoing Endoscopic Ultrasound: 16 Years Experience in a Tertiary Center; The BSG (British Society of Gastroenterology): London, UK, 2021. [Google Scholar]
- Ben, Q.; Zhong, J.; Fei, J.; Chen, H.; Yv, L.; Tan, J.; Yuan, Y. Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors: A Case-Control Study. Sci. Rep. 2016, 6, 36073. [Google Scholar] [CrossRef]
- Gordon-Dseagu, V.L.; Devesa, S.S.; Goggins, M.; Stolzenberg-Solomon, R. Pancreatic cancer incidence trends: Evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. Int. J. Epidemiol. 2018, 47, 427–439. [Google Scholar] [CrossRef]
Figure 1.
Age-adjusted incidence rates for pancreatic ductal adenocarcinoma (PDAC) stratified by age group and sex. (Circle) Incidence rate in women. (Triangle) Incidence rate in men. (A) The average annual percentage change (AAPC) was greater in men compared to women but not statistically significant (0.73% vs. 0.58%); p = 0.001 indicating non-parallel trends among people aged > and =55 years. (B) The AAPC was significantly greater in women compared to men (0.62% vs. −0.09%); p = 0.02 indicating non-parallel trends among people aged 15–54 years. (C) The AAPC was significantly greater in women compared to men (0.62% vs. 0.01%); p = 0.003 indicating non-parallel trends among people aged 35–54 years. (D) The AAPC increased in women and men without a statistically significant difference (3.36% vs. 0.78%); p = 0.04 indicating non-parallel trends among people aged 15–34 years.
Figure 1.
Age-adjusted incidence rates for pancreatic ductal adenocarcinoma (PDAC) stratified by age group and sex. (Circle) Incidence rate in women. (Triangle) Incidence rate in men. (A) The average annual percentage change (AAPC) was greater in men compared to women but not statistically significant (0.73% vs. 0.58%); p = 0.001 indicating non-parallel trends among people aged > and =55 years. (B) The AAPC was significantly greater in women compared to men (0.62% vs. −0.09%); p = 0.02 indicating non-parallel trends among people aged 15–54 years. (C) The AAPC was significantly greater in women compared to men (0.62% vs. 0.01%); p = 0.003 indicating non-parallel trends among people aged 35–54 years. (D) The AAPC increased in women and men without a statistically significant difference (3.36% vs. 0.78%); p = 0.04 indicating non-parallel trends among people aged 15–34 years.
Figure 2.
Age-adjusted incidence rates for pancreatic neuroendocrine tumors (PanNET) stratified by age group and sex. (Circle) Incidence rate in women. (Triangle) Incidence rate in men. (A) The average annual percentage change (AAPC) in PanNET was greater in women compared to men but not statistically significant (7.83% vs. 8.0%); p = 0.01 indicating non-parallel trends among people aged > and =55 years. (B) The AAPC was not significantly different between women and men (6.44% vs. 6.36%); p = 0.72 indicating parallel trends among people aged 15–54 years. (C) The AAPC was not significantly different between women and men (7.10% vs. 6.30%); p = 0.28 indicating parallel trends among people aged 35–54 years. (D) The AAPC was not significantly different between women and men (7.92% vs. 7.32%); p = 0.61 indicating parallel trends among people aged 15–34 years.
Figure 2.
Age-adjusted incidence rates for pancreatic neuroendocrine tumors (PanNET) stratified by age group and sex. (Circle) Incidence rate in women. (Triangle) Incidence rate in men. (A) The average annual percentage change (AAPC) in PanNET was greater in women compared to men but not statistically significant (7.83% vs. 8.0%); p = 0.01 indicating non-parallel trends among people aged > and =55 years. (B) The AAPC was not significantly different between women and men (6.44% vs. 6.36%); p = 0.72 indicating parallel trends among people aged 15–54 years. (C) The AAPC was not significantly different between women and men (7.10% vs. 6.30%); p = 0.28 indicating parallel trends among people aged 35–54 years. (D) The AAPC was not significantly different between women and men (7.92% vs. 7.32%); p = 0.61 indicating parallel trends among people aged 15–34 years.
Table 1.
Sex-specific trends for pancreatic ductal adenocarcinoma (PDAC) stratified by age groups.
| Trends | Comparison between Sex-Specific Trends (p-Value) e | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age Group (Years) | Number of Cases (%) | Time Period | APC a (95% CI) | APC p-Value | AAPC a (95% CI) | AAPC p-Value | AAPC Difference b (95% CI) | AAPC Difference | Test of Coincidence c | Test of Parallelism d |
| All Ages. N = 694,661 | ||||||||||
| Men | 350,616 (50.5%) | 2001–2007 | 1.10 * (0.66–1.53) | <0.001 | 0.65 * (0.48–0.81) | <0.001 | 0.05 (−0.18–0.28) | 0.65 | <0.001 | 0.09 |
| 2007–2018 | 0.40 * (0.25–0.56) | <0.001 | ||||||||
| Women | 344,045 (49.5%) | 2001–2008 | 1.19 * (0.84–1.54) | <0.001 | 0.59 * (0.43–0.76) | <0.001 | ||||
| 2008–2018 | 0.18 * (0.00–0.36) | 0.05 | ||||||||
| Age > and =55. N = 623,552 | ||||||||||
| Men | 308,831 (49.5%) | 2001–2007 | 1.14 * (0.69–1.60) | <0.001 | 0.73 * (0.56–0.91) | <0.001 | 0.15 (−0.10–0.40) | 0.24 | <0.001 | 0.001 |
| 2007–2018 | 0.51 * (0.36–0.67) | <0.001 | ||||||||
| Women | 314,721 (50.5%) | 2001–2008 | 1.15 * (0.76–1.55) | <0.001 | 0.58 * (0.40–0.76) | <0.001 | ||||
| 2008–2018 | 0.19 (−0.02–0.39) | 0.07 | ||||||||
| Age 15–54. N = 71,083 | ||||||||||
| Men | 41,775 (58.8%) | 2001–2018 | −0.09 (−0.32–0.14) | 0.44 | −0.09 (−0.32–0.14) | 0.44 | −0.71 * (−1.07–−0.34) | <0.001 | <0.001 | 0.02 |
| Women | 29,308 (41.2%) | 2001–2018 | 0.62 * (0.30–0.94) | 0.001 | 0.62 * (0.30–0.94) | <0.001 | ||||
| Age 35–54. N = 69,501 | ||||||||||
| Men | 40,918 (58.9%) | 2001–2006 | 1.10 (−0.07–2.30) | 0.06 | 0.01 (−0.35–0.38) | 0.95 | −0.61 * (−1.07–−0.14) | 0.01 | <0.001 | 0.003 |
| 2006–2018 | −0.44 * (−0.74–−0.14) | 0.008 | ||||||||
| Women | 28,583 (41.1%) | 2001–2018 | 0.62 * (0.31–0.93) | 0.001 | 0.62 * (0.31–0.93) | <0.001 | ||||
| Age 15–34. N = 1582 | ||||||||||
| Men | 857 (54.2%) | 2001–2018 | 0.78 (−0.81–2.39) | 0.32 | 0.78 (−0.81–2.39) | 0.32 | −2.59 (−9.28–4.11) | 0.45 | 0.003 | 0.04 |
| Women | 725 (45.8%) | 2001–2003 | 38.20 (−22.21–145.54) | 0.25 | 3.36 (−2.97–10.11) | 0.30 | ||||
| 2003–2018 | −0.56 (−2.42–1.33) | 0.53 | ||||||||
a. APC and AAPC refer to “annual percentage change” and “average annual percentage change”, respectively. * Indicates a significant difference (p < 0.05). Trends were calculated using version 4.9 of the Joinpoint Regression Program (National Cancer Institute). Up to four joinpoints (five line segments) were allowed. The annual percentage change over the whole period (2001–2018) is equal to the average over all the subgroups. b. Negative value indicates greater average APC in women. c. Test of whether sex-specific trends were identical. A significant p-value (p < 0.05) indicates that the trends were not identical (i.e., they had different incidence rates and the coincidence was rejected). d. Test of whether sex-specific trends were equal. A significant p-value (p < 0.05) indicates that the trends were not equal (i.e., they had different incidence rates and parallelism was rejected). e. Multiple testing correction was applied with p-value cutoffs at 0.05 for all ages and the prespecified older and younger adult subgroups, and at 0.025 for the post hoc 35–54 and 15–34 year-old age subgroups.
Table 2.
Sex-specific trends for pancreatic neuroendocrine tumor (PanNET) stratified by age groups.
| Trends | Comparison between Sex-Specific Trends (p-Value) e | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age Group (Years) | Number of Cases (%) | Time Period | APC a (95% CI) | APC p-Value | AAPC a (95% CI) | AAPC p-Value | AAPC Difference b (95% CI) | AAPC Difference | Test of Coincidence c | Test of Parallelism d |
| All ages. N = 42,806 | ||||||||||
| Men | 23,409 (54.7%) | 2001–2010 | 7.35 * (6.38–8.33) | <0.001 | 7.60 * (6.31–8.91) | <0.001 | 0.24 (−1.63–2.12) | 0.80 | <0.001 | 0.58 |
| 2010–2013 | 16.41 * (8.65–24.84) | <0.05 | ||||||||
| 2013–2018 | 3.08 * (1.76–4.41) | <0.001 | ||||||||
| Women | 19,397 (45.3%) | 2001–2010 | 6.83 * (5.85–7.82) | <0.001 | 7.36 * (6.02–8.72) | <0.001 | ||||
| 2010–2013 | 15.77 * (7.67–24.49) | 0.001 | ||||||||
| 2013–2018 | 3.53 * (2.15–4.93) | <0.001 | ||||||||
| Age > and =55. N= 29,788 | ||||||||||
| Men | 16,867 (56.6%) | 2001–2009 | 6.95 * (6.01–7.91) | <0.001 | 8.00 * (7.21–8.80) | <0.001 | 0.17 (−1.87–2.22) | 0.87 | <0.001 | 0.01 |
| 2009–2013 | 15.73 * (12.50–19.05) | <0.001 | ||||||||
| 2013–2018 | 3.81 * (2.83–4.80) | <0.001 | ||||||||
| Women | 12,921 (43.4%) | 2001–2010 | 7.61 * (6.18–9.06) | <0.001 | 7.83 * (5.97–9.74) | <0.001 | ||||
| 2010–2013 | 14.56 * (3.54–26.77) | <0.05 | ||||||||
| 2013–2018 | 4.38 * (2.50–6.29) | <0.001 | ||||||||
| Age 15–54. N= 12,962 | ||||||||||
| Men | 6515 (50.3%) | 2001–2016 | 8.00 * (7.08–8.93) | <0.001 | 6.36 * (4.46–8.28) | <0.001 | −0.10 (−2.66–2.48) | 0.95 | 0.63 | 0.72 |
| 2016–2018 | −5.23 (−18.86–10.68) | 0.47 | ||||||||
| Women | 6447 (49.7%) | 2001–2009 | 5.27 * (3.15–7.44) | <0.001 | 6.44 * (4.74–8.18) | <0.001 | ||||
| 2009–2014 | 13.40 * (8.53–18.49) | <0.001 | ||||||||
| 2014–2018 | 0.55 (−3.19–4.43) | 0.75 | ||||||||
| Age 35–54. N = 11,219 | ||||||||||
| Men | 5763 (51.4%) | 2001–2016 | 7.97 * (6.94–9.02) | <0.001 | 6.30 * (4.16–8.48) | <0.001 | −0.80 (−4.23–2.63) | 0.65 | 0.010 | 0.28 |
| 2016–2018 | −5.47 (−20.70–12.69) | 0.50 | ||||||||
| Women | 5456 (48.6%) | 2001–2003 | 15.48 (−5.00–40.36) | 0.13 | 7.10 * (4.47–9.80) | <0.001 | ||||
| 2003–2009 | 3.43 (−0.22–7.21) | 0.06 | ||||||||
| 2009–2014 | 14.17 * (9.60–18.94) | <0.001 | ||||||||
| 2014–2018 | 0.34 (−3.15–3.95) | 0.83 | ||||||||
| Age 15–34. N = 1743 | ||||||||||
| Men | 752 (43.1%) | 2001–2018 | 7.32 * (5.82–8.83) | <0.001 | 7.32 * (5.82–8.83) | <0.001 | −0.60 (−2.85–1.64) | 0.60 | <0.001 | 0.61 |
| Women | 991 (56.9%) | 2001–2018 | 7.92 * (6.03–9.84) | <0.001 | 7.92 * (6.03–9.84) | <0.001 | ||||
a. APC and AAPC refer to “annual percentage change” and “average annual percentage change”, respectively. * Indicates a significant difference (p < 0.05). Trends were calculated using version 4.9 of the Joinpoint Regression Program (National Cancer Institute). Up to four joinpoints (five line segments) were allowed. The annual percentage change over the whole period (2001–2018) is equal to the average over all the subgroups. b. Negative value indicates greater average APC in women. c. Test of whether sex-specific trends were identical. A significant p-value (p < 0.05) indicates that the trends were not identical (i.e., they had different incidence rates and coincidence was rejected). d. Test of whether sex-specific trends were equal. A significant p-value (p < 0.05) indicates that the trends were not equal (i.e., they had different incidence rates and parallelism was rejected). e. Multiple testing correction was applied with p-value cutoffs at 0.05 for all ages and the prespecified older and younger adult subgroups, and at 0.025 for the post hoc 35–54 and 15–34 year-old age subgroups.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Jiang, Y.; Abboud, Y.; Liang, J.; Larson, B.; Osipov, A.; Gong, J.; Hendifar, A.E.; Atkins, K.; Liu, Q.; Nissen, N.N.; et al. The Disproportionate Rise in Pancreatic Cancer in Younger Women Is Due to a Rise in Adenocarcinoma and Not Neuroendocrine Tumors: A Nationwide Time-Trend Analysis Using 2001–2018 United States Cancer Statistics Databases. Cancers 2024, 16, 971. https://doi.org/10.3390/cancers16050971
AMA Style
Jiang Y, Abboud Y, Liang J, Larson B, Osipov A, Gong J, Hendifar AE, Atkins K, Liu Q, Nissen NN, et al. The Disproportionate Rise in Pancreatic Cancer in Younger Women Is Due to a Rise in Adenocarcinoma and Not Neuroendocrine Tumors: A Nationwide Time-Trend Analysis Using 2001–2018 United States Cancer Statistics Databases. Cancers. 2024; 16(5):971. https://doi.org/10.3390/cancers16050971
Chicago/Turabian StyleJiang, Yi, Yazan Abboud, Jeff Liang, Brent Larson, Arsen Osipov, Jun Gong, Andrew E. Hendifar, Katelyn Atkins, Quin Liu, Nicholas N. Nissen, and et al. 2024. "The Disproportionate Rise in Pancreatic Cancer in Younger Women Is Due to a Rise in Adenocarcinoma and Not Neuroendocrine Tumors: A Nationwide Time-Trend Analysis Using 2001–2018 United States Cancer Statistics Databases" Cancers 16, no. 5: 971. https://doi.org/10.3390/cancers16050971
APA StyleJiang, Y., Abboud, Y., Liang, J., Larson, B., Osipov, A., Gong, J., Hendifar, A. E., Atkins, K., Liu, Q., Nissen, N. N., Li, D., Pandol, S. J., Lo, S. K., & Gaddam, S. (2024). The Disproportionate Rise in Pancreatic Cancer in Younger Women Is Due to a Rise in Adenocarcinoma and Not Neuroendocrine Tumors: A Nationwide Time-Trend Analysis Using 2001–2018 United States Cancer Statistics Databases. Cancers, 16(5), 971. https://doi.org/10.3390/cancers16050971
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
